Pacira Pharmaceuticals, Inc. Announces sNDA Submission For EXPAREL Nerve Block Indication

Published: May 07, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PARSIPPANY, N.J.--(BUSINESS WIRE)--Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a nerve block indication for EXPAREL® (bupivacaine liposome injectable suspension). The sNDA is based on positive data from a Phase 3 study assessing the safety and efficacy of EXPAREL in femoral nerve block for total knee arthroplasty, and will also include additional safety data from a Phase 3 study of EXPAREL used to perform an intercostal nerve block for thoracotomy.

Help employers find you! Check out all the jobs and post your resume.

Back to news